Opinion / How Patent Analytics Can Show Pharma's Top Performers
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
Address: Georg-Glock-Straße 8, 40474 Düsseldorf,Germany
Tel: 0211 – 5 86 01-00
Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of therapeutic, corrective and aesthetic solutions in dermatology. Its expertise spans a broad spectrum of skin, hair and nail diseases. Founded in 1981, Galderma is a joint venture between Nestlé and L’Oréal and employs close to 3.000 people. The company, headed by President & CEO Humberto C. Antunes, has wholly-owned affiliates in 31 countries and a worldwide network of exclusive sales agents. The parent company is based in Lausanne, Switzerland, with Corporate Services in Paris-La Défense, France. In 2008, sales reached 854 million euros, an increase of + 22.4%* over 2007.To drive sustained growth, Galderma invests around 20 percent of revenues in innovation for the development of drugs and other medical solutions which are sourced internally from its own research activities or from partnerships. The R&D staff operates out of 3 specialized sites in the USA, France and Japan.With products sold in more than 65 countries and promoted by a sales force of around 1.000 representatives, Galderma is providing a wide range of innovative medical solutions meeting the highest standards of safety and efficacy. Committed to the future of dermatology, Galderma’s ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meetings the needs of dermatology patients and physicians.
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation…
Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical…
The latest pharma industry news from Germany, including German lobbying efforts against EU pharma legislation; Evonik’s new lipid manufacturing plant; Bayer’s 2023 sales and earnings outlook; Boehringer Ingelheim new biotech…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
At the recent World Economic Forum in Davos, Chair of the Executive Board and CEO of Merck, Belén Garijo, speaking in a session on workforce transformation in the digital era,…
In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the…
See our Cookie Privacy Policy Here